RELMADA THERAPEUTICS, INC. Amortization of Debt Issuance Costs
RELMADA THERAPEUTICS, INC. (RLMD) reported Amortization of Debt Issuance Costs of $6.53 million for the 12-month period ending 2018-06-30, per its 10-KT filed 2020-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2020-03-26
- RELMADA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2018-06-30 was $400.00.
- RELMADA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2017-09-30 was $2.82K.
- RELMADA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2014-06-30 was $57.88K.
- RELMADA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2014-03-31 was $20.84K, a 118.30% increase year-over-year.
- RELMADA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2018 was $6.53M.
- RELMADA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2013 was $69.55K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 115 month | Amortization of Debt Issuance Costs 118 month |
|---|---|---|---|---|---|---|
| 2018-06-30 | $400.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $6.53M 10-KT · filed 2020-03-26 | ||||
| 2018-03-31 | $6.53M 10-Q · filed 2018-05-14 | |||||
| 2017-09-30 | $2.82K 10-Q · filed 2017-11-14 | |||||
| 2014-06-30 | $57.88K derived: 10-K 6 month − 8-K 3 month · filed 2015-09-11 | $78.72K 10-K · filed 2015-09-11 | $118.84K derived: sum of 3 quarters · filed 2015-09-11 | $123.64K derived: sum of 4 quarters · filed 2015-09-11 | ||
| 2014-03-31 | $20.84K 8-K · filed 2014-05-27 | $60.96K derived: sum of 2 quarters · filed 2015-02-13 | $65.76K 10-Q · filed 2015-05-15 | $90.39K 8-K · filed 2014-05-27 | ||
| 2013-12-31 | $40.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13 | $44.92K 10-Q · filed 2015-02-13 | $69.55K 10-K · filed 2015-09-11 | $69.55K 8-K · filed 2014-05-27 | ||
| 2013-09-30 | $4.80K 10-Q · filed 2014-11-07 | |||||
| 2013-03-31 | $9.55K 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |